Author: [email protected]

Amneal Pharmaceuticals Moves to Acquire Kashiv BioSciences in $1.1B+ Deal to Dominate the Biosimilar Wave

Posted on by [email protected]

Amneal Pharmaceuticals (Nasdaq: AMRX) announced on April 21 that it has entered into a definitive agreement to acquire 100% of Kashiv BioSciences, LLC in a transaction that could exceed $1.1 billion in total value — a strategic bet on one of the most significant inflection points in the pharmaceutical industry in decades.

The deal structure includes $375 million in cash and $375 million in equity payable at closing, plus up to $350 million in potential payments tied to regulatory milestones, royalties, and funding of operations through closing. The Manila Times The transaction is subject to Amneal shareholder approval, regulatory clearance, and customary closing conditions, with an expected close in the second half of 2026. The Manila Times

What Kashiv Brings to the Table

Kashiv isn’t just another acquisition target — it’s a rare asset. Kashiv BioSciences is a vertically integrated biopharmaceutical company among the few U.S.-based firms to both manufacture and receive marketing authorization for multiple biosimilars Business Wire, giving it end-to-end capabilities that most companies in the space simply don’t have. That combination of R&D, clinical, manufacturing, and regulatory infrastructure is precisely what Amneal is paying a premium to absorb.

The combined entity is designed to function as a fully integrated global biosimilars platform — built to scale and launch multiple new biosimilar products each year.

The Market Opportunity Driving This Deal

The timing is deliberate. More than $300 billion in global biologics are expected to lose exclusivity over the next decade, and as biosimilars expand patient access while delivering meaningful savings, adoption is accelerating across physicians, patients, and payers. The Manila Times Amneal is positioning itself ahead of that wave rather than chasing it.

The company highlighted $400 million to $500 million in anticipated financial benefits from the transaction, along with a path to maintain a modest leverage profile. TipRanks That’s not a speculative projection — Kashiv already has commercial biosimilars on the market and a robust pipeline moving through regulatory channels.

Strong Financial Momentum Behind the Move

The acquisition announcement came alongside strong preliminary Q1 2026 results that gave management the confidence to pull the trigger. For the quarter ended March 31, 2026, revenue climbed 4% to $723 million, with net income reaching $78 million and significant margin expansion driven by Specialty segment growth and a higher-value product mix. TipRanks On the strength of those results, Amneal raised its standalone full-year 2026 guidance, positioning the Kashiv acquisition as an accelerator of an already-strengthening growth trajectory. TipRanks

Transaction Oversight and Advisors

The transaction was endorsed by an independent conflicts committee TipRanks, a notable governance detail given the pre-existing commercial relationship between the two companies. J.P. Morgan Securities is serving as financial advisor to Kashiv, with Holland & Knight LLP as legal counsel.

The Bottom Line

This deal is a direct statement about where pharmaceutical value creation is headed. As blockbuster biologics lose patent protection at an accelerating clip, the companies with the infrastructure to develop, manufacture, and commercialize biosimilars at scale will control a growing share of one of healthcare’s most important markets. Amneal is making its move now — and the Kashiv acquisition gives it the fully integrated platform to compete at the highest level.

Titan International (TWI) – Model Tweaks Ahead of 1Q26 Earnings

Posted on by [email protected]


Wednesday, April 22, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Model Tweaks. With 1Q26 results to be released next week, we reviewed our assumptions and resulting estimates for the quarter. Titan continues to face inflation and tariff pressure and, more recently, extra pricing pressure from OEMs facing their own end market challenges. In addition, after speaking with management, we were too low on our tax assumption. Given the above, we lowered our earnings expectations, although we are maintaining our revenue and adjusted EBITDA projections.

Details. Revenue for 1Q26 is estimated at $495 million, consistent with our prior expectation. Adjusted EBITDA is $21.5 million, also consistent with our prior projections. We did lower our gross profit assumption to 13.9% from 14.9% and increased our tax expense assumption from $2.5 million to $5 million. As a result of the changes, our projected EPS goes from $0.09/sh to a loss of $0.02 per share.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Greenwich LifeSciences, Inc. (GLSI) – Preliminary FLAMINGO-01 Data Presented At AACR

Posted on by [email protected]


Wednesday, April 22, 2026

Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Phase 3 FLAMINGO-01 Data Presented. Greenwich LifeSciences and the FLAMINGO-01 Steering Committee made two presentations at the American Association of Cancer Research (AACR) 2026 Meeting. One detailed the FLAMINGO-01 trial design while the other presented preliminary results from delayed-type hypersensitivity (DTH) response data showing a statistically significant immune response.

First Poster Presentation Included DTH Data. As discussed in our Research Note on March 18, the company announced a preliminary analysis of recurrence rates in the non-HLA-A*02 arm. Immune responses to GP2 were measured using Delayed-Type Hypersensitivity (DTH) skin tests at baseline, then after 4 or 6 months. This open-label arm of the trial has enrolled about 250 patients, with data reported for 191 patients who completed the six-monthly doses of GLSI-100 at four-month or six-month evaluation points.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Travelzoo (TZOO) – CEO Incentives Signal Turnaround Upside

Posted on by [email protected]


Tuesday, April 21, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Jacob Mutchler, Research Associate, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Shareholders approve CEO option grant. Travelzoo shareholders approved a 600,000-share non-qualified stock option grant to CEO Holger Bartel, formalizing a performance-based compensation structure tied directly to stock price appreciation and marking a clear inflection point in management incentives. The grant represents a significant 5.5% of the current total shares outstanding. 

Structure emphasizes near-term performance and meaningful upside. The options carry a $5.05 exercise price, vest semi-annually over two years, and have a five-year term, creating a relatively short execution window in which management must deliver results to realize value.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Russell Reconstitution 2026, What Investors Should Know

Posted on by [email protected]

The Annual Russell Index Revision and Dates to Watch (2026)

The yearly process of recasting the Russell Indexes begins on Thursday, April 30 and will be complete by market opening on June 29. During the period in between, FTSE Russell will rank stocks for additions, for deletions and evaluate the companies to make sure they conform overall. The methodology for inserting and removing tickers in the Russell 3000, Russell 2000, and Russell 1000 is intentionally transparent to help eliminate price shocks. Price movements do of course occur along the way, and investors try to foresee and capitalize on them. Channelchek will be providing updates that may uncover opportunities, or at least provide an understanding of stock price swings during this period.

Background

Russell index products are widely used by institutional and retail investors throughout the world. There is more than $20.1 trillion currently benchmarked to a Russell index. This includes approximately $12.1 trillion benchmarked to the Russell US Equity indexes. The trading volume of some companies moving into an index will heighten around the last Friday in June as fund managers seek to maintain level tracking with their benchmark target.

Opportunity

For non-passive investing, determining which stocks may benefit from moving up to a large-cap index, down to a smaller one, or into or out of the measurements is an annual event causing volatility around stocks. There has, of course, the potential for very profitable long and short trades. And the potential for an unwitting investor to be holding a company moving out of an index, which could cause less interest in the stock, and perhaps unfortunate performance.

Active investors should make themselves aware of the forces at play so they may either get out of the way or determine if they should become involved by taking positions with those being added or those at the end of their reign within one of the Russell measurements.

Dramatic Valuation Shifts

The leading industries and altered market-cap of companies of a year ago have changed dramatically from last year’s reconstitution. This will be reflected in the 2026 rebalancing and is going to impact a much larger number of companies than most years. That is to say, a higher percentage of companies than normal will move in, out, or to another index, and may be subject to amplified price movement.

The 2026 Russell Reconstitution Schedule:

• Thursday, April 30th – “Rank Day” – Index membership eligibility for 2026 Russell Reconstitution determined from constituent market capitalization at market close.

• Friday, May 22nd – Preliminary index additions & deletions membership lists posted to the FTSE Russell website after 6 PM US eastern time.

•   Friday, May 29th, June 5th, June 12th and Thursday June18th – Preliminary membership lists (reflecting any updates) posted to the FTSE Russell website after 6 PM US eastern time.

• Monday, June 8th – “Lock-down” period begins with the updates to reconstitution membership considered to be final.

• Friday, June 26th – Russell Reconstitution is final after the close of the US equity markets.

• Monday, June 29th – Equity markets open with the newly reconstituted Russell US Indexes.

Take-Away

The annual reconstitution is a significant driver of dramatic shifts in some stock prices as portfolio managers have their holding needs shifted within a very short period of time. Longer-term demand for certain equities is altered as well. Sizable price movements and volatility are expected, especially around the last week in June. In fact, the opening day of the reconstitution is typically one of the highest trading-volume days of the year in the US equity markets.

The market event impacts more than $9 trillion of investor assets benchmarked to or invested in products based on the Russell US Indexes. Portfolio managers that are required to track one of these indexes will work to have minimal portfolio slippage away from their benchmark.  The days and weeks from April 30th through the last Friday in June can create opportunities for investors seeking to benefit from price moves, Channelchek will be covering the event as stocks to be added to, or removed from this year’s Russell Reconstitution and other information plays out.

Eli Lilly’s $7B Kelonia Bet Signals a New Era for CAR-T Therapy — and a Hunting Season for Biotech Targets

Posted on by [email protected]

Eli Lilly is writing another large check in its aggressive diversification push, this time targeting one of oncology’s most promising frontiers. The pharmaceutical giant announced Monday it has agreed to acquire Kelonia Therapeutics in a deal valued at up to $7 billion — $3.25 billion upfront with the remainder tied to clinical, regulatory, and commercial milestones. The transaction is expected to close in the second half of 2026.

The strategic rationale centers on Kelonia’s proprietary in vivo CAR-T technology — a next-generation approach to cancer immunotherapy that sets itself apart from everything currently on the market. Traditional CAR-T treatments require physicians to extract a patient’s T-cells, engineer them in a laboratory setting outside the body, then reinfuse them — a complex, time-consuming process requiring chemotherapy preconditioning and specialized academic medical centers capable of managing the procedure. Kelonia’s platform eliminates all of that. The therapy is delivered intravenously in a single infusion, reprogramming T-cells to attack cancer directly inside the body, with no preconditioning required.

The commercial implications are significant. The existing ex-vivo CAR-T market is already producing blockbuster revenue — Johnson & Johnson’s Carvykti generated nearly $1.9 billion in sales last year for multiple myeloma alone. Gilead recently paid $7.8 billion to acquire Arcellx and its competing asset. A one-time, broadly accessible in vivo alternative that sidesteps the logistical barriers of ex-vivo therapy could expand the addressable patient population dramatically and reach community oncology settings currently unable to administer existing treatments.

For Lilly, this deal is part of a deliberate strategy to reduce its dependence on GLP-1 drugs for obesity and diabetes — the products that have defined the company’s recent run. Management has been explicit: the goal is to deploy the cash flow generated by its weight-loss franchise into therapeutic diversification. Recent deals include Centessa Pharmaceuticals for sleep disorder drugs and Orna Therapeutics for cell therapy. Kelonia extends that footprint into hematology and potentially solid tumors.

What makes this acquisition particularly noteworthy for investors watching the oncology space is what it signals downstream. Lilly’s willingness to spend $3.25 billion upfront on a platform still in early clinical stages — while acknowledging that many early-stage bets will fail — reflects a maturing view of how large pharma is valuing novel modalities. Smaller biotech companies developing differentiated delivery mechanisms, novel immune engineering platforms, or next-generation cell therapies should expect intensifying M&A interest from strategic acquirers flush with capital.

The Kelonia deal also raises the stakes for any company developing competing in vivo CAR-T or similar tumor-targeting platforms. With Lilly now in the race alongside J&J and Gilead, the race to make cancer immunotherapy more accessible — and more scalable — is entering a new, better-funded chapter. For small and microcap biotech names working in adjacent spaces, that’s both a competitive threat and a significant validation of the underlying science.

Two RV Industry Giants Are Circling a Merger That Would Redraw the Outdoor Recreation Supply Chain

Posted on by [email protected]

Two of the most dominant component suppliers in the recreational vehicle and outdoor enthusiast markets may be on the verge of combining. Patrick Industries (NASDAQ: PATK) and LCI Industries (NYSE: LCII) — both headquartered in Elkhart, Indiana — confirmed on April 17 that they are in active discussions regarding a potential merger of equals. Bloomberg first reported the deal would be structured as an all-stock transaction.

The announcement, delivered via separate press releases after Friday’s market close, sent LCI’s trading volume to nearly 3.8 times its 20-day average — a clear signal that the market is treating this as a high-conviction event.

The strategic logic is straightforward. Patrick Industries, founded in 1959, manufactures and distributes component products for the RV, marine, powersports, and housing markets. The company operates more than 190 facilities across a portfolio of over 85 brands and employs more than 10,000 people. LCI Industries, through its Lippert Components subsidiary, is a global leader in engineered components for outdoor recreation and transportation markets, with over 140 manufacturing and distribution facilities across North America, Africa, and Europe.

These are not two fringe players. Together, they supply a substantial portion of the infrastructure that goes into RVs, marine vessels, and powersports units built across North America. A combined entity would carry significant scale advantages — from raw material procurement and logistics to technology investment and aftermarket distribution. As of April 17, Patrick carried a market cap of approximately $3.54 billion and LCI sat at roughly $3 billion. A successful all-stock merger would create an outdoor recreation supply chain player worth approximately $6.5 billion.

The timing is deliberate. The RV industry has been navigating a post-pandemic normalization cycle, with unit shipments softening from their 2021 highs. Consolidation at the supplier tier is a rational response — two companies with overlapping market footprints, shared OEM customers, and comparable operational infrastructure have more to gain together than competing independently. The potential synergies are tangible: combined purchasing power, reduced overhead duplication across facilities, stronger pricing leverage with customers, and a platform large enough to accelerate investment in connected vehicle and smart RV technology.

Historically, LCI has grown through bolt-on acquisitions of product lines and smaller businesses. A merger of equals with Patrick would represent a significant departure from that playbook — a transformational combination rather than incremental expansion. For Patrick, it would provide immediate global distribution reach through Lippert’s international footprint, something the company would otherwise take years to build organically.

There are still material unknowns. No definitive agreement has been signed. Both companies stated they will not comment further until a formal deal is announced or discussions are terminated. Regulatory review of a transaction this size would also be expected, given the combined company’s market share across several RV and marine component categories.

For investors in small and mid-cap industrials, this is a developing story with real consequences for the outdoor recreation supply chain. If Patrick and LCI formalize this combination, it would stand as one of the more significant sector realignments of 2026 — and a signal that the Elkhart manufacturing corridor is entering a new phase of consolidation.

No assurance of a transaction has been given. Watch for an 8-K filing or formal press release for the next material development.

Resolution Minerals Ltd (RLMLF) – Progress on Multiple Fronts

Posted on by [email protected]


Monday, April 20, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Strong Metallurgical Progress. Resolution has advanced metallurgical work at its Antimony Ridge project in Idaho, successfully producing a high-purity antimony trioxide intermediate (99.38% Sb2O3) from stibnite using conventional pyrometallurgical processing. Test work across pyrometallurgy, hydrometallurgy, and ore concentration continues to advance, with further results expected in the near term. The project is supported by high-grade antimony mineralization, consistently exceeding 30% and reaching up to 50%, underscoring its development potential as a domestic source of critical minerals.

Strategic U.S. Processing Opportunity. Resolution is also advancing a strategic plan to establish a U.S.-based antimony processing hub in Idaho, addressing the current lack of modern domestic processing capacity. By leveraging existing infrastructure at the Johnson Creek Mill site, Resolution aims to fast-track development of an integrated “mine-to-product” solution, strengthening supply chains for critical minerals essential to U.S. defense and industrial sectors.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

Euroseas (ESEA) – Updating Estimates to Reflect EM KEA Time Charter Extension

Posted on by [email protected]


Monday, April 20, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Time charter contract extension. Euroseas Ltd. executed a time charter contract extension for the EM Kea at a gross daily rate of $30,000 for a minimum period of 36 months to a maximum of 38 months, at the charterer’s option. The EM Kea is a 2007-built 3,100 twenty-foot equivalent unit (TEU) feeder container ship. The new charter will commence on July 14, 2026, in direct continuation of its present charter. The charter underscores the shortage of prompt tonnage, which, along with macroeconomic disruptions and uncertainty caused by the war in the Middle East, continues to sustain the firmness of the containership market.

Higher rate and improved charter coverage. The new time charter is an improvement over the previous contract rate of $19,000 per day and is expected to contribute EBITDA of $22.5 million during the minimum contracted period. The new time charter enhances charter coverage for 2025, 2026, and 2027 to approximately 91%, 76%, and 44%, respectively.


Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision. 

USA Rare Earth Makes a $2.8 Billion Move to Break China’s Grip on Critical Minerals

Posted on by [email protected]

USA Rare Earth (Nasdaq: USAR) announced this morning a definitive agreement to acquire 100% of Serra Verde Group — owner of the Pela Ema rare earth mine and processing plant in Goiás, Brazil — in a transaction valued at approximately $2.8 billion. The deal is structured as $300 million in cash plus 126.849 million newly issued shares of USAR common stock, based on the company’s April 17 closing price of $19.95.

The acquisition is expected to close in the third quarter of 2026, pending regulatory approvals and customary closing conditions.

This is not a routine tuck-in. It is one of the most strategically significant critical minerals transactions to emerge from the Western world in years — and the timing is deliberate.

Serra Verde’s Pela Ema operation holds a distinction that very few assets in the world can claim: it is the only scaled producer outside of Asia capable of supplying all four magnetic rare earth elements — Neodymium (Nd), Praseodymium (Pr), Dysprosium (Dy), and Terbium (Tb) — at meaningful commercial volumes. These are the materials that go into permanent magnets, which in turn power electric vehicle motors, wind turbines, defense systems, and advanced electronics. China currently controls the overwhelming majority of global rare earth production and processing. Serra Verde represents a direct challenge to that dominance.

The operation is fully permitted and entered production in 2024 after more than $1.1 billion in capital investment. At Phase 1 nameplate capacity — expected to be reached by the end of 2027 — the mine is projected to produce approximately 6,400 metric tons of total rare earth oxide per year and generate annualized EBITDA of $550 to $650 million. The combined company is targeting approximately $1.8 billion in EBITDA by 2030.

The financial structure of this deal is notable beyond the headline price. Serra Verde has already secured a $565 million financing package from the U.S. International Development Finance Corporation to fund optimization and expansion through to positive cash flow. It has also locked in a 15-year, 100% offtake agreement with a special purpose vehicle capitalized by various U.S. government agencies and private capital sources — with guaranteed minimum floor prices for each of the four magnetic rare earths. That government-backed revenue floor substantially de-risks the asset and signals how seriously Washington views rare earth supply chain security as a national priority.

By end of 2027, Serra Verde’s output is expected to represent more than 50% of total non-China heavy rare earth supply globally — a figure that underscores just how critical this asset is to Western supply chain independence.

For USAR, the transaction adds Serra Verde leadership to its board, including Chairman Sir Mick Davis and CEO Thras Moraitis, who will also become President of the combined company. Pro-forma liquidity for the combined entity stands at approximately $3.2 billion.

Moelis & Company acted as exclusive financial advisor to USA Rare Earth. Goldman Sachs advised Serra Verde.

For small-cap investors tracking the critical minerals space, this is the deal that has been anticipated for years — and it closed on one of the most strategically defensible assets available outside of China.

Follow the M&A Money: Why Biotech IPOs Are Making a Comeback

Posted on by [email protected]

Biotech’s long IPO drought may finally be breaking — but don’t mistake a crack in the window for a wide-open door.

This week, two biopharma companies launched roadshows that signal a cautious return of investor appetite to the public markets. GLP-1 developer Kailera Therapeutics hit the road at a $1.9 billion valuation, while proteomics company Alamar Biosciences priced at $17 per share — the top of its marketed range — and opened trading on the Nasdaq Friday with a 33% pop, valuing the company at roughly $1.53 billion. The upsized offering raised $191.3 million, a meaningful signal that institutional demand is real, not manufactured.

But the story isn’t really about IPOs. It’s about M&A.

The primary engine driving this biotech resurgence is an aggressive acquisition cycle fueled by the pharmaceutical industry’s looming patent cliff. Major drug companies are racing to backfill pipelines before blockbuster drugs lose exclusivity, and that urgency is translating into deal flow at a historic pace. According to a Stifel report, 19 biopharma M&A transactions of $1 billion or more were announced between January 1 and April 7 alone — putting the industry on pace for its second-highest annual total ever. Marquee deals include Merck’s $6.7 billion acquisition of Terns Pharmaceuticals and Eli Lilly’s $6.3 billion upfront commitment for Centessa Pharmaceuticals, both announced last month.

That M&A velocity matters beyond the deal itself. When large acquisitions close, venture investors recycle that capital back into the ecosystem — funding the next generation of companies and, critically, making investors more willing to participate in secondary offerings and IPOs. It’s a flywheel, and right now it’s spinning.

Valuations in the private markets are reflecting it. Median pre-money valuations for venture-growth biopharma companies jumped from $65 million to $247 million in 2025, according to PitchBook’s Q4 2025 Biopharma VC Trends report. And the Russell 2000 Biotech Index is up 9.7% year-to-date, outperforming the S&P 500.

That said, the numbers tell a sobering parallel story: of the six biopharma companies that have gone public since January, four are currently trading below their offer price. The market is rewarding quality — and punishing everyone else.

The threshold to go public has risen considerably since the 2020–2021 boom years, when companies with minimal patient data could attract institutional money. Today, clinical-stage companies are bringing 50 or more patients’ worth of data to the roadshow. Pre-clinical companies aren’t even in the conversation.

For small and microcap investors, this environment requires nuance. The biotech IPO window is open — but narrowly, and selectively. Companies that are scientifically de-risked, operationally sound, and well-positioned relative to M&A comps are getting deals done. Everything else is waiting.

The broader implication: as Big Pharma’s acquisition appetite grows, smaller biotech names that could plausibly become targets deserve a closer look. The deals are getting done — the question is who’s next on the list.

Oil Prices Crater 10% as Iran Opens Strait of Hormuz — But Don’t Call It a Done Deal

Posted on by [email protected]

Oil markets were thrown into a volatile session Friday morning after Iran’s foreign minister declared the Strait of Hormuz fully open to commercial traffic for the duration of a fragile 10-day ceasefire between Israel and Lebanon — sending crude prices into a sharp, double-digit freefall.

Brent crude dropped 10%, falling below $90 per barrel, while West Texas Intermediate slid more than 10.5%, pulling below $82. Both benchmarks had opened the week above $100, meaning the week’s loss alone represents one of the most dramatic oil price collapses in recent memory.

The swift selloff reflects just how much of the oil market’s recent premium was baked in around fears of a sustained Strait of Hormuz closure. The strait is the world’s most critical chokepoint for global energy flows, with roughly 20% of all seaborne oil passing through its narrow passage daily. Even a partial disruption sends shockwaves through energy markets — and traders had been pricing in exactly that risk.

The announcement comes as a direct byproduct of the Israel-Lebanon ceasefire that took effect Thursday evening. With that front temporarily cooling, Tehran signaled it could ease its stranglehold on one of the most strategically sensitive waterways on the planet. On the surface, that’s a significant de-escalation.

But energy markets shouldn’t pop the champagne just yet.

Iranian state media clarified Friday that any vessel seeking passage must coordinate directly with the Revolutionary Guard Corps — a requirement that carries its own practical and geopolitical complications for commercial shipowners. It also remained unclear which specific route Iran expects vessels to use, a sticking point that emerged after Iran previously insisted ships pass close to the Iranian coast rather than through more neutral Omani waters.

Adding to the confusion, President Trump posted shortly after the Iranian announcement that while the strait is open, the U.S. naval blockade targeting Iran specifically will remain in full force until a broader deal is finalized. That dual reality — technically open waters but an active American naval presence — leaves shipowners navigating a legal and logistical gray area.

The bigger picture here is a potential U.S.-Iran deal that’s reportedly taking shape. According to reports Friday, Washington is considering a framework that would release roughly $20 billion in frozen Iranian assets in exchange for Iran surrendering its stockpile of enriched uranium. Trump told reporters a deal was looking favorable and that a second round of negotiations could begin as early as this weekend.

For energy investors and small-cap companies with exposure to oil services, exploration, or transportation, Friday’s move is a reminder of how quickly geopolitical sentiment can reprice an entire sector. The energy trade that dominated the first quarter — long crude on Middle East risk — just took a serious gut punch.

Watch the second round of talks carefully. If a deal materializes, energy markets could reprice even further. If talks collapse, expect crude to snap back hard.

The strait may be open. The deal isn’t.

Anthropic Launches Claude Opus 4.7

Posted on by [email protected]

Anthropic is expanding its AI model lineup with the release of Claude Opus 4.7, a new offering the company positions as its most capable generally available model to date — while deliberately keeping its most powerful, and potentially most dangerous, technology off the open market.

The San Francisco-based AI firm says Opus 4.7 delivers meaningful improvements over its predecessor, Claude Opus 4.6, across a range of performance benchmarks including agentic coding, multidisciplinary reasoning, scaled tool use and computer use. For enterprise users and developers, the model is designed to handle complex, real-world workflows more effectively — a direct response to the growing demand for AI that can operate with greater autonomy across business processes.

But what makes this launch notable is not just what Claude Opus 4.7 can do — it’s what it deliberately cannot.

Anthropic has engineered the new model to have reduced cyber capabilities compared to Claude Mythos Preview, the company’s most advanced model, which was rolled out earlier this month to a limited group of companies as part of a new cybersecurity initiative called Project Glasswing. Mythos is not generally available and Anthropic has no near-term plans to change that. The company says it is using Project Glasswing as a controlled environment to study how powerful models behave in real-world cybersecurity contexts before considering any broader release.

With Opus 4.7, Anthropic has embedded safeguards that automatically detect and block requests flagged as prohibited or high-risk cybersecurity uses. The company said it also experimented with training techniques aimed at selectively reducing those capabilities at the model level — not just through filtering after the fact. Security professionals with legitimate use cases can apply through a formal verification program to access those capabilities.

The approach reflects the tightrope Anthropic has walked since its founding in 2021 — building competitive, high-performance AI while maintaining what has become the company’s core differentiator: a reputation for safety-first development. That reputation is now being tested at an entirely new scale.

The launch of Project Glasswing has triggered a wave of high-profile conversations across Washington and Wall Street, with members of the Trump administration, tech executives and bank CEOs meeting to assess what Mythos-class AI capabilities could mean for national security and financial infrastructure. The underlying question — how powerful should a publicly available AI model be — is no longer theoretical.

For investors and enterprises, the practical implications of Opus 4.7 are more immediate. The model is priced identically to Opus 4.6, meaning businesses get a material upgrade at no additional cost. It is available across all Anthropic Claude products, its API and through cloud distribution partners Microsoft, Google and Amazon — giving it broad accessibility across the enterprise ecosystem.

The release also signals something important about where the AI industry is heading. Capability tiers are becoming a deliberate strategic tool. The most powerful models are being gated, studied and selectively deployed — not because they aren’t ready, but because the institutions using them need to be.

For small and mid-cap technology companies building on top of AI infrastructure, the implications are significant. As foundation model providers like Anthropic establish formal verification programs and tiered access structures, third-party developers and SaaS companies will need to navigate an increasingly credentialed ecosystem — one where access to the most powerful tools requires demonstrating not just technical fit, but responsible use.